Zevra Therapeutics (ZVRA) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ZVRA Stock Alerts $4.58 +0.01 (+0.22%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 20 at 12:00 PMDaré Bioscience (NASDAQ:DARE) vs. Zevra Therapeutics (NASDAQ:ZVRA) Head-To-Head Contrastamericanbankingnews.com - April 20 at 6:14 AMQ1 2024 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Boosted by Analystamericanbankingnews.com - April 18 at 5:48 AMZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meetingglobenewswire.com - April 15 at 5:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 12 at 9:30 AMZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facilityglobenewswire.com - April 10 at 7:30 AMZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facilityglobenewswire.com - April 10 at 7:30 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Analystsmarketbeat.com - April 6 at 2:43 AMHC Wainwright Brokers Lift Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 5 at 8:05 AMZevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 4 at 8:05 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 4 at 6:20 PMHC Wainwright Brokers Cut Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 4 at 9:44 AMZevra Therapeutics: Poised for Transformation and Growth Amidst Market Overreactionmarkets.businessinsider.com - April 3 at 6:34 PMBearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimatesfinance.yahoo.com - April 3 at 8:33 AMHC Wainwright Reiterates "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)marketbeat.com - April 3 at 8:24 AMRoth Capital Analysts Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 3 at 5:59 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAstockhouse.com - April 2 at 5:31 PMZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $18.00 at Maxim Groupmarketbeat.com - April 2 at 8:30 AMEquities Analysts Set Expectations for Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)marketbeat.com - April 2 at 6:54 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcriptinsidermonkey.com - April 1 at 1:02 PMZevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 9:09 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price Targetfinance.yahoo.com - March 31 at 1:02 PMZevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 11:47 AMWilliam Blair Research Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - March 29 at 8:37 AMZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMZevra Therapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 9:00 PMZevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatesglobenewswire.com - March 28 at 4:32 PMEarnings Outlook For Zevra Therapeuticsbenzinga.com - March 27 at 2:18 PMZevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomniaglobenewswire.com - March 26 at 4:30 PMZevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - March 25 at 4:30 PMKemPharm Inc (1GDA.DU)finance.yahoo.com - March 19 at 3:34 AMZevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024globenewswire.com - March 18 at 7:30 AMZevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years agofinance.yahoo.com - March 14 at 7:53 PMZevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at William Blairmarketbeat.com - March 12 at 8:21 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Buy" from Brokeragesmarketbeat.com - March 12 at 8:19 AMQ4 2023 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Increased by Analystmarketbeat.com - March 7 at 6:40 AMRoth Capital Comments on Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)marketbeat.com - March 6 at 8:33 AMHC Wainwright Reaffirms "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)marketbeat.com - March 5 at 8:17 AMZevra Therapeutics Says FDA Extends NDA Review Period For Arimoclomolmarkets.businessinsider.com - March 4 at 8:47 AMZevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type Cglobenewswire.com - March 4 at 7:30 AMZevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type Cglobenewswire.com - March 4 at 7:30 AMZevra Therapeutics to Participate at Upcoming Investor Conferencesglobenewswire.com - February 28 at 7:30 AMZevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?finance.yahoo.com - February 15 at 9:24 AMJanney Montgomery Scott LLC Takes $3.25 Million Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - February 15 at 5:31 AM202,773 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Bank of New York Mellon Corpmarketbeat.com - February 10 at 4:13 AMZevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 9:33 AMStrength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?finance.yahoo.com - February 1 at 10:37 AMZevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directorsfinance.yahoo.com - January 23 at 12:29 PMXoma to pay $1M to LadRx as rare disease therapy undergoes FDA reviewmsn.com - January 12 at 8:05 AMZevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type Cfinance.yahoo.com - January 8 at 8:29 AM Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ZVRA Media Mentions By Week ZVRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.780.46▲Average Medical News Sentiment ZVRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼62▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Generation Bio News Design Therapeutics News NuCana News Galectin Therapeutics News Abeona Therapeutics News G1 Therapeutics News Skye Bioscience News Rigel Pharmaceuticals News Omeros News Lifecore Biomedical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
